Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Oxford BioMedica ( (GB:OXB) ) has provided an update.
Oxford Biomedica disclosed that Chief Legal Officer and Group Company Secretary Natalie Walter has exercised 3,816 Deferred Bonus Plan share options at a nil exercise price and subsequently sold the same number of ordinary shares at an average price of £6.145. Chief People Officer Lisa Doman similarly exercised 3,564 Deferred Bonus Plan options at nil cost and disposed of an equivalent number of shares at £6.145, with the dealings reported under EU Market Abuse Regulation as routine PDMR transactions.
The combined sales by the two senior executives amounted to just over £45,000 and represent scheduled movements under the company’s deferred bonus scheme rather than a change in Oxford Biomedica’s operational outlook. These disclosures provide additional transparency for investors around insider share dealings but do not signal any announced shift in the cell and gene therapy CDMO’s strategy or day-to-day business activities.
The most recent analyst rating on (GB:OXB) stock is a Buy with a £1170.00 price target. To see the full list of analyst forecasts on Oxford BioMedica stock, see the GB:OXB Stock Forecast page.
Spark’s Take on OXB Stock
According to Spark, TipRanks’ AI Analyst, OXB is a Neutral.
The score is held back primarily by weak financial performance (still loss-making with negative operating/free cash flow despite improvement) and bearish technicals (price below key moving averages with negative MACD and weak RSI). Valuation provides limited support due to negative earnings and no dividend yield data.
To see Spark’s full report on OXB stock, click here.
More about Oxford BioMedica
Oxford Biomedica (OXB) is a global, quality and innovation-led contract development and manufacturing organisation specialising in cell and gene therapy. The FTSE250-listed group focuses on viral vector development and manufacturing, offering lentiviral, AAV, adenoviral and other vector platforms from early-stage development through to commercial production for biopharma clients worldwide.
With over 30 years of experience in viral vectors, the company operates facilities in Oxfordshire in the UK, Lyon and Strasbourg in France, and Bedford, Massachusetts and Durham, North Carolina in the U.S. Its technology suite includes the TetraVecta fourth-generation lentiviral system, dual-plasmid AAV production and advanced suspension and perfusion processes supported by strong quality and regulatory capabilities.
Average Trading Volume: 335,881
Technical Sentiment Signal: Buy
Current Market Cap: £715.8M
For a thorough assessment of OXB stock, go to TipRanks’ Stock Analysis page.